#ESMO21 Highlights on aspirin use in recurrent platinum-resistent ovarian cancer: EORTC-1508 study

#ESMO22 Highlights on abemaciclib + NSAI in HR+/HER2- advanced breast cancer: The MONARCH 3 studyПодробнее

#ESMO21 Highlights on pembro + chemo in 1st-line metastatic cervical cancer: The KEYNOTE-826 studyПодробнее

#ESMO21 Highlights on atezolizumab combined with FOLFOXIRI + bev in 1st-line mCRC: AtezoTRIBE studyПодробнее

#ESMO21 Highlights on a phase I of dual RAF/MEK inhibitor + FAK inhibitor in ovarian cancer (FRAME)Подробнее

ESMO 2020 Expert Video Report on studying further advanced ovarian cancerПодробнее

#ESMO21 Highlights on combination of pembrolizumab plus chemotherapy in mTNBC: The KEYNOTE-355 studyПодробнее

#ESMO21 Highlights on nivo+ipi vs EXTREME in 1st-line high-risk SCCHN: The CheckMate 651 studyПодробнее

#ESMO21 Highlights on maintenance olaparib in ovarian cancer previously treated with PARPiПодробнее

Aspirin in Combined Breast Cancer Therapy - Oscar GermanПодробнее

Expert report on tackling resistance to CDK4/6 inhibitors in ER+/HER2-metastatic breast cancerПодробнее

ASCO 2023 Highlights on the MIRASOL trial in PT-resistant adv. high-grade epithelial Ovarian CancerПодробнее

PARP Inhibitors in Platinum Sensitive & Platinum Resistant Ovarian CancersПодробнее

Advances in In Vitro Maturation (IVM) of oocytesПодробнее

Unmet clinical needs for platinum-resistant ovarian cancer patientsПодробнее

Managing Platinum-Resistance and Recurrent DiseaseПодробнее

#ESMO21 Highlights on nivolumab in pretreated thymoma & thymic carcinoma: EORTC-ETOP NIVOTHYM studyПодробнее

#ESMO21 Highlights on MFS analysis from comb. treatments in high-risk adv. prostate cancer: STAMPEDEПодробнее